ICON PLC (ICLR)vsNatera Inc (NTRA)
ICLR
ICON PLC
$149.45
-2.19%
HEALTHCARE · Cap: $11.19B
NTRA
Natera Inc
$215.31
-3.06%
HEALTHCARE · Cap: $30.37B
Smart Verdict
WallStSmart Research — data-driven comparison
ICON PLC generates 230% more annual revenue ($8.25B vs $2.50B). ICLR leads profitability with a 2.8% profit margin vs -9.1%. ICLR earns a higher WallStSmart Score of 57/100 (C).
ICLR
Buy57
out of 100
Grade: C
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+61.9%
Fair Value
$349.56
Current Price
$149.45
$200.11 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Distress zone — elevated risk
ROE of 6.4% — below average capital efficiency
2.8% margin — thin
Premium valuation, high expectations priced in
Trading at 17.3x book value
0.0% earnings growth
Weak financial health signals
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ICLR
The strongest argument for ICLR centers on PEG Ratio, Price/Book. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : ICLR
The primary concerns for ICLR are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 50.6x leaves little room for execution misses. Thin 2.8% margins leave little buffer for downturns.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
ICLR profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.54 — expect wider price swings.
NTRA is growing revenue faster at 38.8% — sustainability is the question.
ICLR generates stronger free cash flow (623M), providing more financial flexibility.
Bottom Line
ICLR scores higher overall (57/100 vs 31/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ICON PLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
ICON Public Limited Company, a clinical research organization, provides outsourced marketing and development services in Ireland, the rest of Europe, the United States and internationally. The company is headquartered in Dublin, Ireland.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?